|
【结 构 式】 
|
【分子编号】46306 【品名】(6S)-6-((3R)-3-[(1R,3aR,7aR)-4-[(E)-bromomethylidene]-7a-methyloctahydro-1H-inden-1-yl]butyl)-2,2,3,3,5,5,8,8,9,9-decamethyl-4,7-dioxa-3,8-disiladecane; (2S,5R)-5-[(1R,3aR,7aR)-4-[(E)-bromomethylidene]-7a-methyloctahydro-1H-inden-1-yl]-2-[[tert-butyl(dimethyl)silyl]oxy]-1,1-dimethylhexyl tert-butyl(dimethyl)silyl ether 【CA登记号】 |
【 分 子 式 】C31H61BrO2Si2 【 分 子 量 】601.89914 【元素组成】C 61.86% H 10.22% Br 13.28% O 5.32% Si 9.33% |
合成路线1
该中间体在本合成路线中的序号：(XII)The title compound was synthesized by coupling two structural moieties. The C/D ring fragment (XII) was prepared as shown in Scheme 28478101a. Indane derivative (I) was protected as the acetate ester (II) and subsequently alkylated at the alpha position of the sulfone group with the chiral tosylate (III) to afford (IV). Reductive cleavage of the sulfone group of (IV) by means of sodium amalgam yielded diol (V), which was protected as the acetonide (VI) using 2,2-dimethoxypropane and p-toluenesulfonic acid. Reprotection of the free hydroxyl group of (VI) as the acetate ester (VII), followed by ketal hydrolysis with iodine in MeOH, produced diol (VIII). This was then silylated with tert-butyldimethylsilyl triflate, giving bis-silyl ether (IX). The acetyl group of (IX) was reductively cleaved with LiAlH4, and the resulting alcohol (X) was oxidized to the corresponding ketone (XI) employing N-methylmorpholine-N-oxide in the presence of tetra-n-propylammonium perruthenate (TPAP). Then, Wittig reaction of ketone (XI) with (bromomethylene)triphenylphosphorane furnished the required bromo olefin (XII).
| 【1】 Hatakeyama, S.; et al.; Synthesis and biological characterization of 1alpha,24,25-trihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (24-hydroxylated ED-71). Steroids 2001, 66, 3-5, 267. |
| 【2】 Watanabe, H.; Hatakeyama, S.; Kawase, A. (Chugai Pharmaceutical Co. Ltd.); 24-Hydroxyvitamin D derivs.. EP 1061070; WO 9943645 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 46295 | (1R,3aR,4S,7aR)-7a-methyl-1-[(1S)-1-methyl-2-(phenylsulfonyl)ethyl]octahydro-1H-inden-4-ol | C19H28O3S | 详情 | 详情 | |
| (II) | 46296 | (1R,3aR,4S,7aR)-7a-methyl-1-[(1S)-1-methyl-2-(phenylsulfonyl)ethyl]octahydro-1H-inden-4-yl acetate | C21H30O4S | 详情 | 详情 | |
| (III) | 46297 | (2S)-2,3-dihydroxy-3-methylbutyl 4-methylbenzenesulfonate | C12H18O5S | 详情 | 详情 | |
| (IV) | 46298 | (3S,6S)-6-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl]-2-methyl-5-(phenylsulfonyl)-2,3-heptanediol | C24H38O5S | 详情 | 详情 | |
| (V) | 46299 | (3S,6R)-6-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl]-2-methyl-2,3-heptanediol | C18H34O3 | 详情 | 详情 | |
| (VI) | 46300 | (1R,3aR,4S,7aR)-7a-methyl-1-[(1R)-1-methyl-3-[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]propyl]octahydro-1H-inden-4-ol | C21H38O3 | 详情 | 详情 | |
| (VII) | 46301 | (1R,3aR,4S,7aR)-7a-methyl-1-[(1R)-1-methyl-3-[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]propyl]octahydro-1H-inden-4-yl acetate | C23H40O4 | 详情 | 详情 | |
| (VIII) | 46302 | (1R,3aR,4S,7aR)-1-[(1R,4S)-4,5-dihydroxy-1,5-dimethylhexyl]-7a-methyloctahydro-1H-inden-4-yl acetate | C20H36O4 | 详情 | 详情 | |
| (IX) | 46303 | (1R,3aR,4S,7aR)-1-((1R,4S)-4,5-bis[[tert-butyl(dimethyl)silyl]oxy]-1,5-dimethylhexyl)-7a-methyloctahydro-1H-inden-4-yl acetate | C32H64O4Si2 | 详情 | 详情 | |
| (X) | 46304 | (1R,3aR,4S,7aR)-1-((1R,4S)-4,5-bis[[tert-butyl(dimethyl)silyl]oxy]-1,5-dimethylhexyl)-7a-methyloctahydro-1H-inden-4-ol | C30H62O3Si2 | 详情 | 详情 | |
| (XI) | 46305 | (1R,3aR,7aR)-1-((1R,4S)-4,5-bis[[tert-butyl(dimethyl)silyl]oxy]-1,5-dimethylhexyl)-7a-methyloctahydro-4H-inden-4-one | C30H60O3Si2 | 详情 | 详情 | |
| (XII) | 46306 | (6S)-6-((3R)-3-[(1R,3aR,7aR)-4-[(E)-bromomethylidene]-7a-methyloctahydro-1H-inden-1-yl]butyl)-2,2,3,3,5,5,8,8,9,9-decamethyl-4,7-dioxa-3,8-disiladecane; (2S,5R)-5-[(1R,3aR,7aR)-4-[(E)-bromomethylidene]-7a-methyloctahydro-1H-inden-1-yl]-2-[[tert-butyl(dimethyl)silyl]oxy]-1,1-dimethylhexyl tert-butyl(dimethyl)silyl ether | C31H61BrO2Si2 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XII)Coupling of the A-ring fragment (XXV) and the C/D-ring fragment (XII) to give adduct (XXVI) was carried out in the presence of tris(dibenzylideneacetone) (chloroform)dipalladium and triphenylphosphine. The silyl protecting groups were finally removed by treatment with tetrabutylammonium fluoride.
| 【1】 Hatakeyama, S.; et al.; Synthesis and biological characterization of 1alpha,24,25-trihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (24-hydroxylated ED-71). Steroids 2001, 66, 3-5, 267. |
| 【2】 Watanabe, H.; Hatakeyama, S.; Kawase, A. (Chugai Pharmaceutical Co. Ltd.); 24-Hydroxyvitamin D derivs.. EP 1061070; WO 9943645 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XII) | 46306 | (6S)-6-((3R)-3-[(1R,3aR,7aR)-4-[(E)-bromomethylidene]-7a-methyloctahydro-1H-inden-1-yl]butyl)-2,2,3,3,5,5,8,8,9,9-decamethyl-4,7-dioxa-3,8-disiladecane; (2S,5R)-5-[(1R,3aR,7aR)-4-[(E)-bromomethylidene]-7a-methyloctahydro-1H-inden-1-yl]-2-[[tert-butyl(dimethyl)silyl]oxy]-1,1-dimethylhexyl tert-butyl(dimethyl)silyl ether | C31H61BrO2Si2 | 详情 | 详情 | |
| (XXV) | 46316 | (5R,6R)-6-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-3-butynyl)-2,2,3,3,12,12,13,13-octamethyl-5-vinyl-4,7,11-trioxa-3,12-disilatetradecane; tert-butyl(dimethyl)silyl 3-[[(1R,2R)-2-[[tert-butyl(dimethyl)silyl]oxy]-1-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]-2-propenyl)-4-pentynyl]oxy]propyl ether | C29H60O4Si3 | 详情 | 详情 | |
| (XXVI) | 46317 | (1S,4R)-4-((1R,3aR,7aR)-4-[(E)-2-[(3R,4R,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-4-(3-[[tert-butyl(dimethyl)silyl]oxy]propoxy)-2-methylenecyclohexylidene]ethylidene]-7a-methyloctahydro-1H-inden-1-yl)-1-(1-[[tert-butyl(dimethyl)silyl]oxy]-1-methylethyl)pentyl tert-butyl(dimethyl)silyl ether; (6S)-6-[(3R)-3-((1R,3aR,7aR)-4-[(E)-2-[(3R,4R,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-4-(3-[[tert-butyl(dimethyl)silyl]oxy]propoxy)-2-methylenecyclohexylidene]ethylidene]-7a-methyloctahydro-1H-inden-1-yl)butyl]-2,2,3,3,5,5,8,8,9,9-decamethyl-4,7-dioxa-3,8-disiladecane | C60H120O6Si5 | 详情 | 详情 |